Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Past, present & future of hemophilia treatment: from prophylaxis to gene therapies

VJHemOnc is excited to present the latest developments in the treatment of hemophilia

Read More

FDA approves valoctocogene roxaparvovec gene therapy for adults with severe hemophilia A

On June 29, 2023, the FDA approved the use of valoctocogene roxaparvovec (AAV5-hFVIII-SQ), an adeno-associated virus serotype 5 (AAV5) vector-based…

Read More

EHA 2023 Press Briefing Rundown

VJHemOnc is thrilled to bring you the latest updates from the 28th Congress of the European Hematology Association (EHA) 2023…

Read More

Glofitamab receives FDA approval for adults with relapsed or refractory DLBCL

On June 15, 2023, the U.S Food and Drug Administration (FDA) approved glofitamab for the treatment of adults with relapsed…

Read More

Epcoritamab receives FDA approval for patients with R/R DLBCL and HGBCL

On May 19, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of epcoritamab monotherapy…

Read More

Overcoming R/R myeloma with T-cell engaging therapies

VJHemOnc is excited to bring you highlights from the 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 with leading experts…

Read More

Approaching a cure for multiple myeloma

VJHemOnc is excited to bring you highlights from the 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 with leading experts…

Read More

FDA approves polatuzumab vedotin plus R-CHP for patients with previously untreated DLBCL

On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved the use of polatuzumab vedotin with rituximab, cyclophosphamide,…

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals